---
title: "12 Health Care Stocks Moving In Tuesday's Intraday Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291962859.md"
description: "During Tuesday's intraday session, several healthcare stocks experienced significant volatility. Crinetics Pharmaceuticals surged 98.7% to $83.53, while Tvardi Therapeutics rose 40.04%. Other gainers included Akari Therapeutics and Bluejay Diagnostics. Conversely, Basel Medical Group fell 15.2%, with YD Bio and Conexeu Sciences also declining over 14%. The report highlights major price movements in the healthcare sector."
datetime: "2026-07-07T17:05:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291962859.md)
  - [en](https://longbridge.com/en/news/291962859.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291962859.md)
---

# 12 Health Care Stocks Moving In Tuesday's Intraday Session

### Gainers

-   **Crinetics Pharmaceuticals** (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion.
-   **Tvardi Therapeutics** (NASDAQ:TVRD) stock moved upwards by 40.04% to $2.81. The company's market cap stands at $18.8 million.
-   **Akari Therapeutics** (NASDAQ:AKTX) shares increased by 32.75% to $14.47. The company's market cap stands at $19.0 million.
-   **Bluejay Diagnostics** (NASDAQ:BJDX) stock moved upwards by 31.03% to $1.52. The market value of their outstanding shares is at $1.2 million.
-   **Veraxa Biotech Holding** (NASDAQ:VRXA) shares moved upwards by 21.0% to $2.65. The company's market cap stands at $309.6 million.
-   **Pyxis Oncology** (NASDAQ:PYXS) shares increased by 19.71% to $2.94. The market value of their outstanding shares is at $155.8 million.

### Losers

-   **Basel Medical Group** (NASDAQ:BMGL) shares fell 15.2% to $5.97 during Tuesday's regular session. The company's market cap stands at $11.0 million.
-   **YD Bio** (NASDAQ:YDES) stock declined by 14.96% to $1.99. The market value of their outstanding shares is at $165.7 million.
-   **Conexeu Sciences** (NASDAQ:CNXU) shares decreased by 14.26% to $9.26. The market value of their outstanding shares is at $288.9 million.
-   **Axe Compute** (NASDAQ:AGPU) shares fell 12.49% to $7.36. The company's market cap stands at $95.7 million.
-   **CollPlant Biotechnologies** (NASDAQ:CLGN) stock declined by 12.33% to $0.38. The market value of their outstanding shares is at $5.4 million.
-   **Forum Markets** (NASDAQ:FRMM) shares fell 12.05% to $5.99. The company's market cap stands at $89.9 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [CRNX.US](https://longbridge.com/en/quote/CRNX.US.md)
- [AKTX.US](https://longbridge.com/en/quote/AKTX.US.md)
- [TVRD.US](https://longbridge.com/en/quote/TVRD.US.md)
- [BJDX.US](https://longbridge.com/en/quote/BJDX.US.md)
- [BMGL.US](https://longbridge.com/en/quote/BMGL.US.md)
- [CNXU.US](https://longbridge.com/en/quote/CNXU.US.md)
- [YDES.US](https://longbridge.com/en/quote/YDES.US.md)
- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)
- [PYXS.US](https://longbridge.com/en/quote/PYXS.US.md)
- [AGPU.US](https://longbridge.com/en/quote/AGPU.US.md)
- [CLGN.US](https://longbridge.com/en/quote/CLGN.US.md)
- [FRMM.US](https://longbridge.com/en/quote/FRMM.US.md)
- [YDESW.US](https://longbridge.com/en/quote/YDESW.US.md)

## Related News & Research

- [Tvardi Therapeutics plans 2027 mid-to-late stage ulcerative colitis trial for STAT3 inhibitor TTI-109](https://longbridge.com/en/news/294357121.md)
- [Bluejay Diagnostics Completes Enrollment in SYMON-II Sepsis Study](https://longbridge.com/en/news/293531257.md)
- [YD Bio launches cancer testing pilot with Numia Health in Canada](https://longbridge.com/en/news/294062286.md)
- [LiveOne, Inc. (NASDAQ:LVO) Sees Large Decline in Short Interest](https://longbridge.com/en/news/294238652.md)
- [PowerCompute Regains Compliance with Nasdaq Minimum Bid Price Requirement | PWCM Stock News](https://longbridge.com/en/news/294179666.md)